Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income

ARTIVION, INC.

Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.
Non-GAAP net income $6.3M ($0.13/share) vs $10.7M ($0.24/share) in Q2 2025; adjusted EBITDA $26.4M, up 7% YoY.
On-X revenue grew 18% constant currency; stent grafts grew 12% constant currency; AMDS and NEXUS highlighted.
Received U.S. FDA PMA approval for AMDS Hybrid Prosthesis; completed acquisition of Endospan Ltd. in May 2026.
Reiterated FY2026 revenue guidance $480-496M (7-11% constant currency growth) and adjusted EBITDA $92-99M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.